FDA Inspections of Clinical Investigators
This guidance is intended to provide information about FDA inspections of clinical investigators conducted under FDA’s Bioresearch Monitoring (BIMO) Program. This document supersedes FDA’s Information Sheet Guidance, "FDA Inspections of Clinical Investigators," dated January 2006. This document has been revised to provide updated information and is being issued in accordance with the agency’s regulations on Good Guidance Practices (21 CFR 10.115).
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.